Appl. No.: 09/766,362 Patent
Art Unit: 1516 PDC 119 (1951300-00047)

Reply to Office Action of 11/16/2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim Listing:

- 1. (Currently Amended) A composition for the nasal administration of a drug in a dry powder form suitable for administration to the nasal region, the dry powder form comprising microparticles comprising the drug and a diketopiperazine wherein said microparticles haveing a particle size of between about 10 microns to and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns microparticles comprising the drug and a diketopiperazine.
- 2. (Original) The composition of claim 1 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.
- 3. (Original) The composition of claim 2 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.
- 4. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.
- 5. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.
 - 6. (Cancelled)
- 7. (Currently Amended) A drug delivery device for nasal administration comprising
- a drug in a dry powder form in a dosage formulation for administration to the nasal region and,
 - a device for delivering a measured dose of the drug to the nasal mucosa,

Appl. No.: 09/766,362 Patent
Art Unit: 1516 PDC 119 (1951300-00047)

Reply to Office Action of 11/16/2007

wherein the dry powder form comprises microparticles <u>comprising the</u> <u>drug and a diketopiperazine and said microparticles</u> haveing a particle size of <u>between about 10 microns</u> to <u>and about 20 microns</u> in diameter and <u>wherein more than 50% of the microparticles have a particle size greater than about 10 microns comprising the drug and a diketopiperazine.</u>

- 8. (Original) The device of claim 7 wherein the device is a nasal insufflator.
- 9. (Original) The device of claim 7 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.
- 10. (Original) The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.
- 11. (Previously Presented) The device of claim 7 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.
- 12. (Previously Presented) The device of claim 7 wherein the diketopiperazine diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.
 - 13. (Cancelled)
- 14. (Currently Amended) A method of administering a drug to the nasal region of a patient in need thereof, comprising nasally administering a dry powder suitable for nasal administration, wherein the dry powder form comprises microparticles comprising the drug and a diketopiperazine and said microparticles haveing a particle size of between about 10 microns to and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns and comprising the drug and a diketopiperazine.
- 15. (Original) The method of claim 14 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

Appl. No.: 09/766,362 Patent
Art Unit: 1516 PDC 119 (1951300-00047)

Reply to Office Action of 11/16/2007

16. (Original) The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

- 17. (Previously Presented) The method of claim 14 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.
- 18. (Previously Presented) The method of claim 14 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.
 - 19. (Cancelled)
- 20. (Previously Presented) The composition of claim 1 formed by spray drying.
- 21. (Previously Presented) The device of claim 7 wherein the microparticles are formed by spray drying.